Below is a list of included studies and their ancillary publications (indented below main results publication):

1. Andersen MR, Drescher CW, Zheng Y, et al. Changes in cancer worry associated with participation in ovarian cancer screening. Psychooncology. 2007;16(9):814-20. PMID: 17225260. http://dx.doi.org/10.1002/pon.1151 [PubMed: 17225260]
   1. Drescher CW, Nelson J, Peacock S, et al. Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening. Cancer Epidemiol Biomarkers Prev. 2004;13(4):600-6. PMID: 15066925 [PubMed: 15066925].
2. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295-303. PMID: 21642681. http://dx.doi.org/10.1001/jama.2011.766 [PubMed: 21642681]
   1. Lai T, Kessel B, Ahn HJ, et al. Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer. J. 2016;27(4):e41. PMID: 27102249. https://dx.doi.org/10.3802/jgo.2016.27.e41 [PMC free article: PMC4864517] [PubMed: 27102249]
   2. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005;193(5):1630-9. PMID: 16260202. http://dx.doi.org/10.1016/j.ajog.2005.05.005 [PubMed: 16260202]
   3. Croswell JM, Kramer BS, Kreimer AR, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med. 2009;7(3):212-22. PMID: 19433838. http://dx.doi.org/10.1370/afm.942 [PMC free article: PMC2682972] [PubMed: 19433838]
   4. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113(4):775-82. PMID: 19305319. http://dx.doi.org/10.1097/AOG.0b013e31819cda77 [PMC free article: PMC2728067] [PubMed: 19305319]
   5. Pinsky PF, Yu K, Kramer BS, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol. 2016. PMID: 27615399. http://dx.doi.org/10.1016/j.ygyno.2016.08.334 [PMC free article: PMC5077651] [PubMed: 27615399]
   6. Pinsky PF, Zhu C, Skates SJ, et al. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Int J Cancer. 2013;132(9):2127-33. PMID: 23065684. http://dx.doi.org/http://dx.doi.org/10.1002/ijc.27909 [PubMed: 23065684]
3. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945-56. PMID: 26707054. 10.1016/s0140-6736(15)01224-6 [PMC free article: PMC4779792] [PubMed: 26707054]
   1. Barrett J, Jenkins V, Farewell V, et al. Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS). BJOG. 2014;121(9):1071-9. PMID: 24865441. http://dx.doi.org/10.1111/1471-0528.12870 [PubMed: 24865441]
   2. Jenkins V, Fallowfield L, Langridge C, et al. Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. Int J Gynecol Cancer. 2015;25(8):1519-25. PMID: 26222482. http://dx.doi.org/10.1097/IGC.0000000000000507 [PMC free article: PMC4582418] [PubMed: 26222482]
   3. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327-40. PMID: 19282241. http://dx.doi.org/10.1016/S1470-2045(09)70026-9 [PubMed: 19282241]
   4. Menon U, Ryan A, Kalsi J, et al. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol. 2015;33(18):2062-71. PMID: 25964255. 10.1200/JCO.2014.59.4945 [PMC free article: PMC4463475] [PubMed: 25964255]
   5. Sharma A, Burnell M, Gentry-Maharaj A, et al. Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound Obstet Gynecol. 2016;47(2):228-35. PMID: 26095052. http://dx.doi.org/10.1002/uog.14929 [PMC free article: PMC4755159] [PubMed: 26095052]
4. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353(9160):1207-10. PMID: 10217079. http://dx.doi.org/10.1016/s0140-6736(98)10261-1 [PubMed: 10217079]
   1. Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993;306(6884):1030-4. PMID: 8490497. http://dx.doi.org/10.1136/bmj.306.6884.1030 [PMC free article: PMC1677033] [PubMed: 8490497]